Cyclic urea compounds, preparation thereof and pharmaceutical use thereof as kinase inhibitors

US7825115B2 · kind B2 · utility

Assignee

• AVENTIS PHARMA S.A. · FR

Inventors

• Marcel Patek · Tucson, US
• Anil Nair · Tucson, US
• Augustin Hittinger · Igny, FR
• Conception Nemecek · Thiais, FR
• Daniel Bond · Tucson, US
• Greg Harlow · Boulder, US
• Herve Bouchard · Thiais, FR
• Jacques Mauger · Tucson, US
• Jean-Luc Malleron · Marcoussis, FR
• Mark G. Palermo · Rindge, US
• Fahad Al-Obeidi · Tucson, US
• Thomas H. Faitg · Collegeville, US
• Hartmut Strobel · Liederbach, DE
• Sven Ruf · Mainz, DE
• Kurt Ritter · Heidelberg, DE
• Youssef El-Ahmad · Créteil, FR
• Dominique Lesuisse · Montreuil, FR
• Didier Benard · Villiers-le-Bel, FR

Key dates

• Filing date: Jan 10, 2008
• Grant date: Nov 2, 2010
• Expiry date: Jul 24, 2028

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D401/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The disclosure relates to a cyclic urea compound of formula I:as defined herein, to the process for its preparation, pharmaceutical composition comprising it and its pharmaceutical use as an inhibitor on a protein kinase. Thus, the compound of formula I is useful for preventing or treating a physiological disorder capable of being modulated by inhibiting the activity of a protein kinase, such as a solid tumor.